Elsevier

Autoimmunity Reviews

Volume 6, Issue 3, January 2007, Pages 155-161
Autoimmunity Reviews

The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias

https://doi.org/10.1016/j.autrev.2006.09.008Get rights and content

Abstract

Mammalian cells are provided with surface-bound complement regulatory proteins that protect them from uncontrolled complement-mediated lysis. Two of these regulators in humans, CD55 and CD59, are glycosylphosphatidylinositol-anchored, type I cell surface proteins, which inhibit formation of the C3 convertases and prevent the terminal polymerization of the membrane attack complex, respectively. Paroxysmal nocturnal hemoglobinuria is a genetic disorder due to the impaired conformation of the glycosylphosphatidylinositol-anchor, that results in the deficient expression of CD55 and CD50 which leads to excessive destruction of red cells and leukocytes. We have studied the expression of these two molecules in patients with autoimmune hemolytic anemia, autoimmune thrombocytopenia, and patients with systemic lupus erythematosus showing lymphopenia, and found that all three types of cytopenias are associated to deficient expression of CD55 and CD59 on the involved hematopoietic lineage. These are the first descriptions of acquired deficiencies of complement regulatory molecules in human disease, and it seems, from our results, that such deficiencies might play a pathogenic role in the mechanism of cell destruction. Although autoantibodies appeal as the best candidates to cause underexpression of CD55 and CD59, the search for an association to the presence and titers of most frequent self-reactive antibodies has proved non-existent.

Introduction

Discovered over a century ago, the complement system has been traditionally envisioned as a cascade of soluble serum proteins whose sequential activation eventually results in cell lysis. Additionally, several by-products of the activation of such proteins are capable to recruit inflammatory cells [1]. The highly efficient defensive role of complement in infectious diseases has never been questioned, but its capability to mediate damage to self in several instances is also recognized [2], [3]. Whether activated by antibodies directed to self or non-self antigens, or by means of other triggering substances, the explosive and unspecific activation of the common final pathway of the complement system might be harmful to healthy neighboring cells and tissues in a process that has been known as the damage to the “innocent bystander”. To counteract or contain self-damage, the complement system has many regulators, both soluble and membrane-bound, which appear to be more or less efficient in distinct conditions. Normal cells resist complement-mediated lysis, by several mechanisms comprising a self-recognition system [4]. This system is composed primarily of specific membrane-bound proteins such as decay accelerating factor (DAF, CD55) [5], membrane cofactor protein (CD46) [6], and homologous restriction factor (membrane inhibitor of reactive lysis [MIRL], protectin, CD59) [7]. Complement receptor type 1 (CD35) is also involved in the regulation of C3 fragment deposition [8]. This review focuses on CD55 and CD59, and their possible pathogenic role in autoimmune hemocytopenias.

Section snippets

CD55

Also named DAF, CD55 is a single chain, glycosylphosphatidylinositol (GPI)-anchored, type I cell surface protein. It inhibits formation of the C3 convertases through binding to C3b and C4b. It also binds the alternate pathway convertase C3bBb, the classical pathway convertase and C4b2a to accelerate their decay. Inasmuch as it works optimally with human complement, while not with complement of other species, it is commonly said to show homologous restriction [9]. The function of CD55 is to

CD59

Also called MIRL or protectin, CD59 is a single chain, GPI-anchored cell surface protein structurally homologous to snake venom neurotoxins [17], which is broadly expressed on cells from all tissues. Its expression on erythrocytes is important for their survival upon homologous complement activation [18]. CD59 protects cells from complement mediated lysis through binding C9, inhibiting its incorporation into the C5b-9 complex and preventing the terminal polymerization of the membrane attack

Paroxysmal nocturnal hemoglobinuria, the original link between complement regulators and human disease

Paroxysmal nocturnal hemoglobinuria (PNH) is an ancient but accurate term to describe the clinical manifestation of red cell lysis and release of hemoglobin into the urine that is manifested most prominently by dark-colored urine in the morning. The term “nocturnal” refers to the belief that the hemolytic episode was triggered by acidosis during sleep and activates complement to hemolyse an abnormally susceptible red cell membrane. However, this last observation has been disproved with time,

Autoimmune hemolytic anemia

Three years ago we published what seems to be the first description of the acquired deficiency of complement regulators in humans [24]. In this study, we evaluated the membrane density of CD55 and CD59 in erythrocytes from patients with autoimmune hemolytic anemia (AIHA) and its possible relation with the presence of anti-phospholipid antibodies. We studied 19 patients with AIHA, eleven of which fulfilled at least four of the American College of Rheumatology diagnostic criteria for systemic

Concluding remarks

When we initiated this series of studies, we hypothesized that autoantibodies, most likely those bearing reactivity towards phospholipids, could be responsible for the decreased expression of complement regulatory proteins CD55 and CD59. Antibodies with phospholipid reactivity might hinder the binding of the proteins to the GPI anchorage, or shed the GPI-protein complexes from the cell surface of erythrocytes, platelets and lymphocytes. In the case of lymphocytes, internalization of

Take-home messages

  • CD55 and CD59 are glycosylphosphatidylinositol (GPI)-anchored proteins with complement inhibitory properties. Congenital deficiency of the expression of these proteins, as in paroxysmal nocturnal hemoglobinuria, lead to augmented sensitivity to complement mediated lysis, which results in hemolytic anemia.

  • Patients with autoimmune hemolytic anemia, autoimmune thrombocytopenia, and with systemic lupus erythematosus with lymphopenia, have an acquired deficiency of CD55 and CD59 on the involved

References (39)

  • M.J. Telen et al.

    The Inab phenotype: characterization of the membrane protein and complement regulatory defect

    Blood

    (1989)
  • P.J. Lachmann

    The control of homologous lysis

    Immunol Today

    (1991)
  • Y. Richaud-Patin et al.

    Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus

    Immunol Lett

    (2003)
  • M.J. Walport

    Complement

    N Engl J Med

    (2001)
  • T.R. Welch

    Complement in glomerulonephritis

    Nat Genet

    (2002)
  • M.K. Storch et al.

    Multiple sclerosis: in situ evidence of antibody-and complement-mediated demyelination

    Ann Neurol

    (1998)
  • M.K. Liszewski et al.

    Control of the complement system

    Adv Immunol

    (1996)
  • A. Nicholson-Weller et al.

    Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system

    J Immunol

    (1982)
  • T. Seya et al.

    Purification and functional properties of soluble forms of membrane cofactor protein (MCP, CD46) of complement: identification of forms increased in cancer patients' sera

    Int Immunol

    (1995)
  • A. Davies et al.

    CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

    J Exp Med

    (1989)
  • L.A. Hebert

    Clearance of immune complexes from the circulation of man and other primates

    Am J Kidney Dis

    (1987)
  • A. Nicholson-Weller et al.

    Structure and function of decay accelerating factor CD55

    J Lab Clin Med

    (1994)
  • R.W. Finberg et al.

    Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells

    J Immunol

    (1992)
  • A. Nicholson-Weller et al.

    Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor

    Proc Natl Acad Sci U S A

    (1983)
  • M.K. Pangburg et al.

    Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria

    Proc Natl Acad Sci U S A

    (1983)
  • N.A. Clarkson et al.

    Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding

    J Virol

    (1995)
  • D.R. Shafren et al.

    Coxsackie viruses B1, B3 and B5 use decay accelerating factor as a receptor for cell attachment

    J Virol

    (1995)
  • G.T. Spear et al.

    Host-cell derived complement control proteins CD55 and CD59 are incorporated in to the virions of two unrelated enveloped viruses. Human T Cell leukemia/lymphoma virus type I (HTLV-1) and human cytomegalovirus (HCMV)

    J Immunol

    (1995)
  • B. Kieffer et al.

    Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins

    Biochemistry

    (1994)
  • Cited by (82)

    • Autoimmune diseases

      2022, Clinical Immunology
    • Autoimmune hemolytic anemia

      2019, The Autoimmune Diseases
    • Hematologic and lymphoid abnormalities in SLE

      2018, Dubois' Lupus Erythematosus and Related Syndromes
    View all citing articles on Scopus
    1

    Tel.: +52 55 5655 5954; fax: +52 55 55732996.

    View full text